Genexine, Inc. 095700
KRX · South Korea · Health Technology
KRW 2,770.00-35.00 (-1.25%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
SEOUL, South Korea, September 15, 2026--Genexine, Inc. (KOSDAQ: 095700) announced that Jaehyun Choi, Ph.D., CEO and Head of R&D, presented new preclinical data for GX-BP1, the company’s SOX2-targeting bioPROTAC, at the 2026 World Conference on Lung Cancer (WCLC) in Seoul on September 13.
Egret Therapeutics, Inc. ("Egret"), a clinical-stage biotechnology company developing novel immune-modulatory therapies for secondary inflammation following traumatic and ischemic disorders, today announced the signing of a non-binding Memorandum of Understanding (MOU) with Genexine, Inc. (KOSDAQ: 095700) to acquire full right, title, and interest in its lead asset, GX-P1 (also known as EGT-101).
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.